alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
← catalyst calendarSponsored by Celyad Oncology SA (industry) · CYAD.BR — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
49estimated
Sites
4
Countries
Belgium, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-11-28 | actual | When the study began enrolling |
| Primary completion | 2021-11-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2036-02-17 | estimated | The whole study's end, after follow-up |
| First posted | 2018-10-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2020-11-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Unresectable Metastatic Colorectal Cancer
Interventions
- Drug: CYAD-101
- Drug: FOLFOX
- Drug: FOLFIRI
Primary outcome
what the primary-completion date above is the date OFOccurence of Dose Limiting Toxicities
measured Up to 82 days post first CYAD-101 Infusion
Publications
- PMID 35191428 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · CYAD.BR's whole pipeline · Catalyst calendar · Every registered study · What changed